Competition

Competition — who can hurt Molina, who it can beat

Molina is the smallest of the large US managed-care organizations and the most concentrated: a pure-play government-sponsored insurer whose entire book is Medicaid, Medicare duals, and the low-income Marketplace [1]. That focus is the source of its moat — a low administrative cost base it uses to win state contracts on price — and also the source of its fragility: it has none of the vertical integration or product diversification that lets UnitedHealth, CVS/Aetna, and Elevance absorb a bad medical-cost year. In 2025 the whole sector hit one, and Molina's earnings fell harder than most.

The bottom line

Molina's consolidated medical care ratio (MCR) — claims paid as a share of premium, the single most important profitability lever in this business — jumped to 91.7% in 2025 and to 94.6% in the fourth quarter, driving net income down by roughly 60% year over year. The advantage Molina sells to states (low cost, government-program expertise) is intact; what 2025 proved is that the advantage does not protect the earnings when the cost cycle turns.

Sources: revenue and net income per reported financials, FY2025 10-K [2]; consolidated MCR 91.7% and ~5.5M members across 21 states [3].

The arena and the peer set

Molina competes inside one industry — managed care for government-sponsored populations — and it names its rivals directly. In its FY2025 10-K it lists its primary Medicaid competitors as Centene, CVS Health, Elevance, and UnitedHealth, and notes "increasing competition driven by renewed interest from large national health plans" [4]. In Medicare it competes against CVS Health, Humana, and UnitedHealth, and its primary low-income Marketplace competitor is Centene [5]. That gives a self-selecting peer set of five government-program MCOs. Each runs a managed-care risk model confirmed from its own latest 10-K:

• Centene (CNC) — "the largest Medicaid health insurer in the country, serving 12.5 million Medicaid members in 30 states" [6]. The closest direct substitute to Molina in both Medicaid and low-income Marketplace.
• UnitedHealth (UNH) — its UnitedHealthcare Community & State unit "serves consumers who are economically disadvantaged, the medically underserved," i.e. Medicaid, alongside Medicare & Retirement for seniors [7].
• CVS Health (CVS) — through Aetna's Health Care Benefits segment, offers "Medicare Advantage… and Medicaid health care management services" [8]. Also Molina's PBM vendor via CVS Caremark [9].
• Elevance (ELV) — "approximately 45.2 million medical members," offering managed care across "Individual, Employer Group, Medicaid and Medicare markets" [10].
• Humana (HUM) — "83% of our total premiums and services revenue were derived from contracts with the federal government," chiefly Medicare Advantage; ~15 million medical members [11]. Molina's overlap is in Medicare and duals, not Medicaid.

Cigna (CI) is excluded from the core set. It is a large managed-care/health-services group, but Molina does not name it among its primary Medicaid, Medicare, or Marketplace competitors — Cigna is organized around Evernorth pharmacy services and commercial insurance and appears only in Molina's stock-performance peer index. It is carried below as a secondary comparator with valuation only, not benchmarked as a direct rival.

Sources: rivalry and business overlap per Molina FY2025 10-K Competition section [12] [13]; peer business models per each peer's own FY2025 10-K [14] [15] [16] [17] [18]; market caps from staged competitor snapshots, as of 2026-06-26; revenue/net margin derived from reported FY2025 financials. EV is not reliably disclosed in the corpus and is shown blank rather than invented.

Every public competitor named anywhere in this tab carries a market cap above; enterprise value is N/A for all because a reliable net-debt figure for each peer is not present in the corpus or structured data, and inventing a capital structure would be worse than disclosing the gap.

Scale: Molina is the minnow in a pool of whales

The first thing the peer set reveals is sheer size disparity. Molina's ~$12B market value and ~$45B of revenue sit at the bottom of a group whose largest member, UnitedHealth, is worth more than 30× as much and books nearly 10× the revenue. Size is not decorative in this industry: it funds the medical-cost data, the provider leverage, and the balance sheet that let a rival ride out a bad year.

Source: revenue and net margin derived from reported FY2025 financials; bubble size = market cap from staged competitor snapshots, as of 2026-06-26 [19].

Note where Centene sits — a negative net margin in 2025. Its Marketplace book swung to a loss as the morbidity of the risk pool rose faster than its premiums; Centene disclosed the mechanism in its own filing, describing how individuals entering and exiting the market raise morbidity "without a proportionate change to risk adjustment" and the need to set premium deficiency reserves [20]. Molina avoided that fate in Marketplace by deliberately shrinking its exposure — but the same cost-trend force hit its Medicaid and Medicare books instead.

Where Molina wins

Molina's edge is operating focus translated into cost, and a credentialed track record that keeps states handing it contracts.

• Lowest administrative cost in the peer group. Molina's G&A ratio was just 6.6% in 2025 (6.7% in 2024), which management attributes to "operating discipline" and operating leverage as it grows [21]. A thin admin load is the core of the bid Molina takes to a state: it can quote a competitive premium and still clear margin. Its vision statement makes the positioning explicit — "the low-cost, most effective and reliable health plan delivering government-sponsored care" [22].
• Pure-play focus that diversified giants cannot fully match. Because Molina does only government-sponsored care, it tunes its provider networks and utilization management to those populations, which it says gives "a competitive unit cost position and quality service levels" [23], and a "singular focus on government-sponsored healthcare" that lets it "identify and implement efficiencies" [24]. For a UNH or CVS, Medicaid is one unit among many; for Molina it is the whole company.
• Winning new contracts even in a hard year. In 2025 Molina was awarded an Illinois Fully Integrated Dual Eligible (FIDE-SNP) contract that began January 2026, and was the sole plan selected for Florida's "Florida Kids" program (~120,000 enrollees) [25]. These are competitive RFP wins, not renewals — evidence the low-cost pitch still converts.
• Duals integration is a structural tailwind it is positioned for. Management argues that "states promoting the integration of Medicaid and Medicare supports the long-term competitive position of our duals products" [26]. The dual-eligible population is the highest-value, stickiest government cohort, and Molina's footprint is built around it.

Where competitors are better

The same focus that makes Molina efficient leaves it exposed where scale and diversification matter.

• Vertical integration — Molina has none. UnitedHealth owns Optum (care delivery, data, PBM), CVS owns Caremark and a pharmacy/clinic network, Elevance has Carelon, and Humana has CenterWell. Molina buys its pharmacy benefits from a competitor — it runs "a long-standing PBM agreement with CVS Caremark" [27]. Rivals capture margin across the value chain and gain cost-trend visibility that a pure payer lacks.
• Diversification cushions the medical-cost cycle. In 2025 Molina's earnings fell sharply because nearly 100% of its profit pool is medical-claims risk. UnitedHealth and Elevance, with services revenue and broader books, held net margins near 2.7–2.8% while Molina's collapsed to ~1.0% — they have non-risk earnings to lean on when the MCR spikes.
• Centene out-scales Molina in their shared core. In Medicaid — Molina's largest segment — Centene's 12.5 million members in 30 states [28] dwarf Molina's ~4.6 million, and Centene brands itself "the nation's largest managed care company focused on underserved populations" [29]. Greater scale means more bargaining leverage with providers and more states across which to spread fixed cost.
• Balance-sheet depth to absorb shocks. A bad Marketplace or Medicaid year is survivable for a $377B UnitedHealth or a $133B CVS in a way it is not for a $12B Molina. The capacity to keep bidding through a downturn — and to acquire distressed books — sits with the larger players.

The margin cycle — the real competitive event of 2025

The most important competitive fact about Molina right now is not a lost contract; it is that the entire sector's medical costs outran its premiums, and Molina, with the least cushion, felt it most. The Medicaid MCR rose 150 bp to 91.8% on higher utilization, member-acuity shifts, and rate increases that "have lagged the increase in medical cost trend, resulting in a rate and trend imbalance" [30]. The Medicare MCR rose 330 bp to 92.4% on high-acuity duals utilization, prompting Molina to exit MAPD in thirteen states [31].

Source: consolidated MCR by year per reported financials; FY2025 detail and rate-trend commentary, FY2025 10-K MD&A [32].

On share, the picture is more stable than the earnings: Molina's Medicaid membership has stayed range-bound (4.33M in 2021, 4.89M peak in 2024, 4.57M in 2025), and total membership held near 5.2–5.5M across five years — the recent dip reflects industry-wide Medicaid redeterminations, not defection to a named rival. Molina is holding competitive share while the economics of that share have temporarily deteriorated.

Source: segment membership per reported financials; FY2025 total ~5.5M across 21 states per FY2025 10-K [33].

Threat assessment

Sources: rate-trend imbalance and Medicaid/Medicare MCR pressure, FY2025 10-K MD&A [34] [35]; APTC expiry and Marketplace volatility, FY2025 10-K Risk Factors [36]; OBBBA Medicaid morbidity and integrated-rival entry, Molina FY2025 10-K [37] and Centene FY2025 10-K [38]; PBM dependence [39].

Why the top two are High. The rate-trend imbalance directly compressed every Molina segment in 2025 and is the most likely force to keep margins below target into 2026; Molina calls it "temporary" but cannot control the timing of state rate catch-up [40]. The Marketplace threat is acute because enhanced premium tax credits "expired at the end of 2025"; their non-renewal both shrinks the subsidized membership Molina serves and worsens the morbidity of who remains [41] — the same dynamic that pushed Centene into a Marketplace loss. Molina has already chosen to "reduce our exposure in this highly volatile segment" and to stay "cautious" approaching the 2027 pricing cycle [42].

Moat watchpoints

The few signals that would actually change the competitive call:

1. Medicaid MCR vs the long-term target. Molina says the 91.8% Medicaid MCR is "above our long-term target range" [43]. A return toward the high-80s confirms the imbalance was cyclical; a persistent reading near or above 92% means the model's pricing power is structurally eroding.
2. RFP win/loss rate on re-procurements. Track each state contract that comes up for rebid. Wins like Florida Kids and Illinois duals [44] validate the low-cost moat; a string of losses to integrated rivals would signal that "renewed interest from large national health plans" [45] is converting into share loss.
3. G&A ratio. The 6.6% admin ratio is the quantified moat [46]. If it drifts up toward peers', the price advantage Molina takes to states narrows.
4. Medicaid membership trajectory post-redetermination. Watch whether membership re-stabilizes around the ~4.5–4.6M base or keeps sliding — the test of whether the recent dip was redetermination noise or genuine share erosion.
5. 2027 Marketplace pricing posture and APTC outcome. Whether Congress renews the enhanced subsidies [47], and how aggressively Molina re-prices versus Centene, will decide whether Marketplace is a growth lane or a managed retreat.